Research programme: protein kinase inhibitors - PIQUR Therapeutics

Drug Profile

Research programme: protein kinase inhibitors - PIQUR Therapeutics

Alternative Names: PQR-311; PQR-316; PQR-3xx; PQR-401; PQR-514; PQR-530; PQR-620

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator PIQUR Therapeutics
  • Class Antineoplastics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Janus kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain disorders; Cancer; Eye disorders; Lymphoma; Skin disorders; Solid tumours

Most Recent Events

  • 08 Feb 2017 Preclinical trials in Solid tumours in Switzerland (unspecified route), before February 2017 (PIQUR Therapeutics pipeline)
  • 11 Jan 2017 PIQUR Therapeutics and Pierre Fbare enter into a collaborative agreement for co-development of PQR 309 for dermato-oncology indications
  • 09 Jan 2017 Preclinical trials in Lymphoma in Switzerland (unspecified route), before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top